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Open access under CC BY-NWe propose a novel bottom-up approach to the bounding of low-dose human cancer risks from chemical
exposures that does not rely at all upon high-dose data for human or animal cancers. This approach can
thus be used to provide an independent ‘‘reality check’’ on low-dose risk estimates derived with dose-
response models that are ﬁt to high-dose cancer data. The approach (1) is consistent with the ‘‘additivity
to background’’ concept, (2) yields central and upper-bound risk estimates that are linear at all doses, and
(3) requires only information regarding background risk, background (endogenous) exposure, and the
additional exogenous exposure of interest in order to be implemented. After describing the details of this
bottom-up approach, we illustrate its application using formaldehyde as an example. Results indicate
that recent top-down risk extrapolations from occupational cohort mortality data for workers exposed
to formaldehyde are overly conservative by substantial margins.
 2013 Elsevier Inc. Open access under CC BY-NC-ND license. 1. Background
In 1976, Kenny Crump, David Hoel, Charles Langley, and Richard
Peto published a landmark paper (Crump et al., 1976) showing that
a non-decreasing dose–response relationship for cancer risk will be
linear at sufﬁciently low doses as long as there is a non-zero back-
ground exposure to which the speciﬁc chemical exposures of inter-
est simply add. This is the well-known ‘‘additivity to background’’
concept: at zero additional exposure, we are already somewhere
up on the dose–response curve as a result of our non-zero back-
ground exposure, so the slope of the dose–response relationship
at zero additional exposure will necessarily be non-zero and posi-
tive. Even a threshold dose–response relationship will have a non-
zero slope at zero additional exposure if there are some individuals
in the population of interest whose thresholds lie below their non-
zero background exposure.
Then, in 1977, Crump, Harry Guess, and K.L. Deal published an-
other landmark paper (Crump et al., 1977) that outlined the statis-
tical and mathematical procedures for estimating and bounding
the low-dose slope of the multistage dose–response model using
constrained maximum likelihood methods and tumor data col-
lected in laboratory animal bioassays conducted at very high expo-
sure levels. It was in this paper that the now infamous ‘‘q1⁄’’, the
upper 95% conﬁdence bound on the coefﬁcient of the linear termrr), jswenber@email.unc.edu
C-ND license. (i.e., the low-dose slope) of the presumed dose–response relation-
ship, was created, and this value has dominated carcinogenic risk
assessment ever since.
The dominance of q1⁄ in risk assessment has been a conse-
quence of two factors. First, there is the tyranny of small numbers,
i.e., the small numbers of animals that have been utilized in labo-
ratory animal carcinogenicity studies, typically, only about 50 ani-
mals per sex per dose group. This number is so small that even if
the observed tumor incidence in a treated group is zero (0/50),
the exact binomial upper 95% conﬁdence bound on the true re-
sponse probability is 0.0582, so true risks up to this value cannot
be conﬁdently ruled out. It is also not possible to distinguish statis-
tically at the p = 0.05 level between a response as high as 0.08 (4/
50 tumor-bearing animals) in a treated group and a null response
(0/50) in a control group using Fisher’s exact test. If the goal of risk
assessment is to bound the dose of a chemical that is associated
with an upper bound incremental cancer risk of only one per mil-
lion (106), then one can conservatively ‘‘guesstimate’’ the required
dose, using the low-dose linear hypothesis, as being about
100,000-fold lower than the highest dose that produces no signif-
icant increase, compared to controls, in the probability of develop-
ing cancer. This is common knowledge among biostatisticians, and
a source of frustration and heartburn among many toxicologists; it
is, nevertheless, an irrefutable ‘‘fact of life’’.
The second factor behind the dominance of q1⁄ is that until re-
cently, the background exposures that may be responsible, at least
in part, for our background cancer risks have not been quantiﬁed
(two notable exceptions are radiation and our background body
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Fig. 1. Illustrating the ‘‘bottom-up’’ approach to bounding additional human cancer
risks that may be associated with low level chemical exposures. P0 is the
background lifetime risk of a tissue-speciﬁc cancer. C0 and C0L are the central and
lower 95% conﬁdence bound estimates of the steady-state background concentra-
tion of speciﬁc DNA adducts linked to the cancer in the same tissue. b and bu are the
bottom-up central and upper 95% conﬁdence bound estimates of the low-dose
slope of the cancer risk-DNA adduct relationship.
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been focused on quantifying background chemical exposures, and
the exposures of interest have routinely been expressed as incre-
ments above whatever the background exposures might be. This
is primarily due to the fact that human background exposures
are complicated, uncontrolled, and usually unmeasured, while
the animal studies that attempt to carefully control and minimize
these background exposures have not routinely included measures
of the corresponding internal (endogenous) doses that can arise via
normal metabolism and other internal biochemical reactions.
Without knowing what background exposure is, expressed
preferably as the concentration of a relevant exposure bio-
marker, e.g., DNA adducts, in the target tissue of interest, the
only way to estimate the slope of the dose–response relationship
at low doses has been via downward extrapolation from the ob-
served tumor responses in small numbers of animals (or occupa-
tionally exposed people) at high external exposure levels, which
forces us into the q1⁄conundrum. However, this situation has
changed recently, and the change could profoundly alter carcin-
ogenic risk assessment going forward, at least for those poten-
tially carcinogenic substances that are always present in our
bodies, even absent external exposure, because they are pro-
duced continuously by normal biochemical processes such as
metabolism and biochemical synthesis and degradation. The
key technological advance underpinning our novel ‘‘bottom-up’’
approach to risk assessment is the extraordinary ability to dis-
tinguish between and separately quantify the relevant internal
exposures in target tissues that arise from internal background
(endogenous) and external (exogenous) sources. In what follows,
we outline this alternative approach to estimating and bounding
low-dose cancer risks for such substances, and illustrate the po-
tential for its application with the speciﬁc example of formalde-
hyde, an important commodity chemical that is currently under
review by the US Environmental Protection Agency (USEPA).2. The bottom-up approach
Let P0 represent the background lifetime risk of a tissue-spe-
ciﬁc cancer in people, such as nasopharyngeal cancer or leuke-
mia. Let C0 represent the mean tissue-speciﬁc background
steady-state concentration of a biomarker, such as a speciﬁc
DNA adduct, that is presumed to be causally related to these
cancers. Then the ratio P0/C0 provides an estimate of the low-
dose slope of the relationship between the cancer risk and the
corresponding tissue-speciﬁc DNA adduct concentration. Simi-
larly, if C0L represents the lower 95% conﬁdence bound estimate
for the same background adduct concentration, then the ratio P0/
C0L provides an upper 95% conﬁdence bound on the low-dose
slope. This latter ratio is thus directly comparable to the q1⁄ de-
rived from high dose animal studies, as well as the upper bound
slope estimates for the low-dose linear dose–response relation-
ships that are typically inferred from epidemiologic analyses of
occupational cohort cancer mortality, provided only that the
dose metrics used in these two kinds of studies (animal bioas-
says and cohort mortality studies) are converted into the corre-
sponding equivalent tissue-speciﬁc adduct concentrations.
The key elements of this bottom-up approach are illustrated
in Fig. 1. What is most important to appreciate is that the cen-
tral and upper bound slope estimates derived using this ap-
proach do not depend in any way on high-dose carcinogenicity
data for laboratory animals or humans. The approach thus pro-
vides a completely independent ‘‘reality check’’ on low-dose
slope estimates like q1⁄ that are derived from analyses of high-
dose laboratory animal tumor incidence data or occupational
cancer mortality data.3. An illustration of the bottom-up approach using currently
available data for formaldehyde
Formaldehyde is a highly reactive chemical and an essential
metabolic intermediate that is generated endogenously in all living
cells, and N2-hydroxymethyl-deoxyguanosine (dG) adducts have
been detected and quantiﬁed in various tissues of rats (Lu et al.,
2010 and 2011) and cynomolgus macaques (Moeller et al., 2011)
exposed to various concentrations of stable isotope-labelled
[13CD2]-formaldehyde by inhalation. These formaldehyde-DNA ad-
ducts are potentially promutagenic because adduction takes place
on the amino groups participating in Watson–Crick base pairing,
and adduct formation is widely considered to be a key event in
the initiation of mutations that lead to carcinogenesis (Swenberg
et al., 2011). Thus, the tissue-speciﬁc concentration of these ad-
ducts provides an excellent internal dose metric with which to
illustrate the bottom-up approach to bounding the low-dose slope
of dose–response relationships for human cancer risk.
The use of [13CD2]-formaldehyde permits the simultaneous
measurement of both endogenous and exogenous formaldehyde-
DNA adducts with sensitive Liquid Chromatography–Electrospray
Ionization-TandemMass Spectrometry-Selected Reaction Monitor-
ing (LC–ESI-MS/MS-SRM) methods. While endogenous dG adducts
were detected in all of the examined tissues, exogenous dG adducts
formed with inhaled [13CD2]-formaldehyde were detected only in
the tissues taken from the site of initial contact with exogenous
formaldehyde, i.e., rat and monkey nasal respiratory epithelium
(Swenberg et al., 2011).
Because no exogenous dG adductswere detected in these studies
in any distant site tissues, including bonemarrow and the blood, we
can statewith conﬁdence that if such exogenous adductswere pres-
ent in these tissues, then their amountswouldnecessarily have been
smaller than the LC–ESI-MS/MS-SRMmethod’s detection limit (DL).
We have therefore used the method’s DL (reported in Moeller et al.
(2011) as 20  1018 mol) as a worst case upper bound on the level
of exogenousdGadducts that couldbe present andyet remainunde-
tected in the bone marrow of [13CD2]-formaldehyde-exposed mon-
keys. The above molar DL was converted to an equivalent DL
expressed in terms of the number of adducts, namely, 1.03  103
per 107dG, using the average amount of monkey DNA collected in
the bone marrow samples (Moeller et al., 2011), and the amount of
guanine (0.20, expressed as a fraction) that is present in monkey
DNA (Casanova et al., 1991).
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slope calculations are provided in Table 1. These values are the
mean ± standard error of the number of endogenous and exoge-
nous dG adducts per 107dG in nasal respiratory epithelium
(2.49 ± 0.23 and 0.25 ± 0.020, respectively), and the bone marrow
(17.5 ± 1.31, endogenous dG adducts only) as determined in mon-
keys following two 6 h exposures to 2 ppm [13CD2]-formaldehyde
(data taken from Table 3 in Swenberg et al., 2011). Also presented
are the lower 95% conﬁdence bound estimates for endogenous dG
adducts in both tissues, i.e., the mean values minus 1.645 times
their respective standard errors.
We have also estimated the corresponding steady-state exoge-
nous dG adduct levels that would result from continuous 24 h/day,
7 days/week exposure. To accomplish this, we used the adduct lev-
els measured inmonkeys byMoeller et al. (2011) immediately after
the two 6 h exposures (30 h after the onset of the ﬁrst exposure), to-
gether with a simple one compartment linear kinetic model of ad-
duct buildup and elimination with a 63 h elimination half-life
(mean adduct lifetime T = 63/ln(2) = 90.9 h) as has been determined
in rats (Swenberg et al., 2012). For example, if Cx30 represents the
measured exogenous DNA adduct concentration after two 6 h
exposures on consecutive days to a given airborne formaldehyde
concentration, and CxS–S represents themodel-predicted asymptotic
steady-state adduct concentration that would result from continu-
ous exposure to the same airborne formaldehyde concentration,
then CxS–S = Cx30/{[1–exp(6/T)]  [1 + exp(24/T)]} = 8.85⁄Cx30.
The steady-state adduct concentrations that are predicted by this
formula to arise from continuous lifetime exposure to 2 ppm
[13CD2]-formaldehyde are also provided in Table 1.
At present, we do not have estimates of endogenous or exoge-
nous dG adduct concentrations in human tissues, so we have made
the simple assumption that the DNA adduct data collected byMoel-
ler et al. (2011) in cynomolgusmacaques are directly relevant to hu-
mans without any interspecies scaling adjustments. For the
background lifetime risks of developing nasopharyngeal cancer
(NPC) and leukemia (LEU), we have relied on two different sources.
For NPC, we have taken the estimate of 7.25  104 that is provided
in USEPA’s 2 June 2010 draft formaldehyde assessment (see Table C-
1, p C-3 and Section 5.2.2). For leukemia, we used the Both Sexes, All
Race lifetime risk estimate of 1.3  102 from Table 1.14 of
SEER Cancer Statistics Review 1975–2007 (Altekruse et al., 2010).
Table 2 presents the results from using the bottom-up approach
with these data and assumptions to calculate upper boundTable 1
Endogenous and exogenous DNA adduct concentrations (per 107dG) in nasal epithelial tiss
consecutive days to 2 ppm [13CD2]-formaldehyde (data taken from Moeller et al. (2011)). A
are expected to result from lifetime continuous inhalation exposure to 2 ppm [13CD2]-form
Tissue Endogenous adducts at 30 h
Nasal epithelium mean ± se
lower 95% bound
2.49 ± 0.23
2.11
Bone marrow mean ± se
lower 95% bound
17.5 ± 1.31
15.34
a No exogenous adducts were detected in bone marrow; upper limits estimate based
Table 2
Comparison of estimated lifetime risks of developing nasopharyngeal cancer
to 1 ppm formaldehyde, as estimated with the bottom-up approach and
epidemiologic data (as taken from Table 6–3, pp 6–41-6–42 of the Agency’s
Cancer Background risk, P0 Bottom-up slope, P0/C0La
NPC 7.25  104 3.44  104
LEU 1.30  102 8.50  104
a for NPC, 3.44  104 = 7.25  104/2.11
for LEU, 8.50  104 = 1.30  102/15.3.
b for NPC, 0.038  102 = 3.44  104  (2.21/2)
for LEU, <3.9  106 = 8.50  104  (<0.00912/2).estimates of human nasopharyngeal cancer and leukemia risk from
lifetime continuous exposure to 1 ppm formaldehyde. To obtain
bottom-up estimates corresponding to 1 ppm formaldehyde, we
ﬁrst calculated bottom-up estimates for 2 ppm (the lowest expo-
sure level used by Moeller et al. (2011), and then simply divided
those estimates by a factor of two, since the bottom-up approach
assumes linearity of the dose–response relationship. We chose
1 ppm so as to be able to compare our risk estimates simply and
directly with those derived by USEPA from epidemiologic data
using cumulative formaldehyde exposure as the dose metric,
namely 0.011 ppm1 for NPC and 0.057 ppm1 for leukemia (see
Table 6–3, pp 6–41- 6–42 of the Agency’s draft assessment).
For nasopharyngeal cancer (NPC), the bottom-up upper bound
risk estimate (0.038  102) is nearly 29-fold lower than USEPA’s
‘‘plausible upper bound’’ estimate of 1.1  102, i.e., about 1%. In
contrast, the bottom-up upper bound estimate of leukemia risk
(<3.9  106) is more than 14,000-fold lower than the correspond-
ing USEPA estimate of 5.7  102, i.e., about 6%. The marked dis-
parity between these estimated cancer risks for this distant site
suggests strongly that the excess risk of leukemia that has been re-
ported in association with workplace formaldehyde exposures is
not due to those exposures. If our plausible assumption that form-
aldehyde dG adducts provide a valid molecular dosimeter for relat-
ing potential human cancer risks to formaldehyde exposure is
correct, then the much larger risks derived by USEPA from the
adult human cancer data are overly conservative.4. Strengths and limitations of the bottom-up approach
We are conﬁdent that the estimates obtained from this simple
approach to bounding low-dose human cancer risks are conserva-
tive for several reasons. Most importantly, the bottom-up approach
attributes all of the background risk of speciﬁc cancers to the
endogenous formaldehyde dG adducts that are found in the corre-
sponding tissues. If only a fraction f of the total background risk P0
were due to the background endogenous adduct concentration C0,
then it is only this fraction of the total background risk P0 to which
our assumed linear dose–response relationship should apply. The
slope estimate P0/C0 and the associated upper 95% conﬁdence
bound described herein would therefore exaggerate the actual
slope of the low-dose response and its upper estimated 95% conﬁ-
dence bound by the factor 1/f.ue and bone marrow of cynomolgus macaques exposed via inhalation for 6 h on two
lso shown are the 8.85-fold higher steady-state exogenous adduct concentrations that
aldehyde (see text for details).
Exogenous adducts at 30 h Exogenous adducts at steady-state
0.250 ± 0.020 2.21 ± 0.18
<0.00103a <0.00912a
on the detection limit reported in Moeller et al. (2011).
(NPC) and leukemia (LEU) from continuous lifetime inhalation exposure
, alternatively, by USEPA using top-down linear extrapolation from
2 June 2010 draft assessment).
Bottom-up risk at 1 ppmb USEPA risk at 1 ppm
0.038  102 1.1  102
<3.9  106 5.7  102
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sumes linearity at all doses. This can create problems if we extrap-
olate the bounding bottom-up risk estimates to very high
exogenous exposure levels, such as those producing statistically
signiﬁcant increases in tumor incidence in exposed laboratory ani-
mals or humans. At such levels, it is expected that the dose–re-
sponse relationship for tumor incidence may well be highly non-
linear due to a variety of factors that become important only at
high doses, such as cytotoxicity, tissue damage, and enhanced cell
proliferation that markedly increases the probability of mutations.
Such non-genotoxic high dose phenomena are not accounted for in
our simple linear model, so the conﬁdence bounds that it generates
should not be expected to hold at the high exogenous exposures
where these phenomena take place.
Third, we have used lower 95% conﬁdence bounds on the esti-
mated mean endogenous DNA adduct levels (C0) to generate, by
simple inversion, the corresponding upper 95% conﬁdence bounds
on the slope (P0/C0) of the linear relationship that has been as-
sumed between cancer risks and steady-state adduct concentra-
tions. This follows directly from a Taylor series expansion of the
ratio P0/C0 about its expected value when P0 is taken to be constant,
as we have assumed herein, and only the estimated mean back-
ground DNA adduct concentration C0 has uncertainty associated
with it. In this special case, the variance of the ratio P0/C0 is given
approximately by (c.f., Stuart and Ord, 1994, p. 351):
VarðP0=C0Þ=ðP0=C0Þ2  VarðC0Þ=C20 ð1Þ
If uncertainty in the estimate of the mean background risk P0 is
also characterized and it is independent of, i.e., uncorrelated with,
the uncertainty in C0, as is the case herein, because the estimates of
P0 and C0 are derived from two completely different data sets, then
the additional uncertainty in the estimated ratio P0/C0 that is due
to the uncertainty in P0 can also be readily accommodated (ibid.):
VarðP0=C0Þ=ðP0=C0Þ2  VarðC0Þ=C20 þ VarðP0Þ=P20: ð2Þ
The upper 95% conﬁdence bound on the slope estimate P0/C0 is
thus increased as a result of incorporating the additional uncer-
tainty in P0. Additional discussion of uncertainty in the estimate
of the ratio P0/C0 in a linear regression context is provided in the
Appendix.
Fourth, for the case of leukemia, exogenous DNA adducts were
never detected in monkey bone marrow even though the method-
ology has sufﬁcient statistical power to detect a single N2-hydroxy-
methyl-deoxyguanosine adduct in 10 billion deoxyguanosine
molecules. We have therefore assumed, as a worst case, that exog-
enous DNA adducts could have been present at a level just barely
below the detection limit of the ultrasensitive LC–ESI-MS/MS-
SRM methodology. One could reduce this estimate substantially
using less conservative assumptions regarding the sampling distri-
bution of non-detected exogenous DNA adduct concentrations (c.f.,
Ginevan and Splitstone, 2003, pp 123–125).
Fifth, we have made reasonable assumptions in converting ad-
duct concentrations measured in monkey tissues after two 6 h/day
exposures to 2 ppm airborne formaldehyde on consecutive days to
the higher steady-state adduct levels that would arise from contin-
uous exposures to the same airborne formaldehyde concentration
for a lifetime, but our extrapolation using a simple linear pharmaco-
kinetic model has not yet been validated. Data from longer term
studies out to 28 consecutive days of exposure are currently being
analyzed, so the remaining uncertainty regarding the half-life of
formaldehyde DNA adducts should be better resolved in due course.
Even so, the cross-species extrapolation from DNA adduct data
obtained in monkeys to human formaldehyde exposures remains
unvalidated. However, unvalidated assumptions can be replaced
at some point with data-driven alternatives. For example, in thenear future, we expect to obtain data regarding endogenous form-
aldehyde dG adducts in human tissues. Human blood samples are
readily obtainable, and opportunistic sampling of other critical tis-
sues such as nasal tissue and bone marrow is certainly possible.
Such data could be used to conﬁrm and/or replace our plausible
dosimetric assumption that endogenous formaldehyde dG adduct
amounts in monkey and human tissues are directly comparable.
Obtaining exogenous adduct concentrations in humans may be
more problematic. However, the extraordinary sensitivity of the
Lu et al. (2010, 2011) and Moeller et al. (2011) methodology may
offer the prospect of detecting such adducts using short-term vol-
untary human exposures.
Finally, another important limitation of the bottom-up ap-
proach is its reliance on the assumption of a linear dose–response
relationship between cancer risks and DNA adduct concentrations
in target tissues, even though the true dose–response may be
highly nonlinear at sufﬁciently high exogenous exposure levels.
For this reason, we advocate the bottom-up approach only as a po-
tential means for generating tighter upper bounds on low-dose hu-
man cancer risks than it may be possible to achieve with top-down
approaches. The bottom-up approach may not be appropriate for
developing ‘‘best’’ or central estimates of low-dose human cancer
risks which, at least in our view, can best be accomplished through
a comprehensive and deep mechanistic understanding of how
chemical exposures give rise to human cancer.5. Summary
The Lu et al. (2010, 2011) and Moeller et al. (2011) LC–ESI-MS/
MS-SRM methodology differentiates clearly between DNA adducts
formed with formaldehyde molecules of endogenous and exoge-
nous (inhaled) origin. This remarkable technological achievement
has made it possible to develop upper-bound estimates of poten-
tial cancer risk with a unique bottom-up approach that extrapo-
lates upward from background (endogenous) exposures and
background cancer risks, as opposed to the typical top-down
extrapolations from cancer incidence in laboratory animals or hu-
man workers subjected to very high exposure levels.
While we have illustrated the bottom-up approachwith the exam-
ple of formaldehyde, we expect it to be readily generalizable to other
chemicals. For example, vinyl chloride, ethylene oxide, methanol,
and acetaldehyde are all known to produce speciﬁc DNA adducts from
endogenous and exogenous sources, and other chemicals are likely to
be added to this list in the near future. The target tissue dose concept
can also be generalized to include other forms of endogenous DNA
damage, such as abasic sites, lesions arising from oxidative stress,
and also biomarkers of effect, such as mutations (Swenberg et al.,
2008, 2011). The potential of the bottom-up approach to impact hu-
man cancer risk assessment appears great.
We used the new molecular dosimetry information for formal-
dehyde DNA adducts in the bottom-up approach to estimate
upper-bound lifetime human nasopharyngeal cancer and leukemia
risks that might arise from continuous inhalation exposure to
1 ppm formaldehyde. This provides a totally independent ‘‘reality
check’’ on estimates derived with the conventional top-down ap-
proach to human cancer risk assessment. Comparison of the result-
ing bottom-up risk estimates with corresponding top-down
estimates derived by USEPA from epidemiologic data for exposed
workers show the latter to be markedly higher. The large discrep-
ancies between the results we obtained with molecular dosimetry
data incorporated into the bottom-up approach and those that re-
lied on worker cancer mortality and uncertain retrospective occu-
pational exposure reconstructions call into serious question the
credibility of attributing large increases in human mortality from
these cancers to occupational formaldehyde exposure.
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Appendix A
An anonymous reviewer pointed out to us that estimation of an
upper percentile conﬁdence bound on the slope of the dose–re-
sponse curve near the background exposure level C0 can also be
considered in the context of linear regression, with the regression
line forced through the origin (c.f., Neter et al., 1996, pp 159–163).
The situation we are concerned with here is a special one, because
there is only one Y value, namely P0, which is derived from national
cancer statistics, i.e., the Yi (P0i) values that would be associated in
a regression context with the n individual Xi measurements of the
background endogenous DNA adduct concentration (C0i) are actu-
ally all equal to the single mean background risk estimate P0. Given
this constraint, it is not difﬁcult to show algebraically that the
slope estimate b1 resulting from linear regression through the ori-
gin of the equal Yi on the individual C0i is given by:
b1 ¼ P0=C0  =f1þ ððn 1Þ=nÞ  VarðC0Þ=C20g; ð3Þ
where Var(C0) is the estimated variance of the C0i. So long as Var(C0)
is small compared to C02, the term in curly brackets in Equation 3
will be close to unity in value, and the regression slope estimate
b1 will be approximately equal to P0/C0, but in any case, b1 will al-
ways be smaller than the ratio P0/C0. Thus P0/C0 will be a conserva-
tive, i.e., larger, estimate of the low-dose slope than the linear
regression estimate b1 given in Equation 3.
In addition, the estimated variance of the regression slope esti-
mate b1 for this special case of equal Yi can be shown algebraically
to be given by:
Varðb1Þ ¼ b21  ½ðVarðC0Þ=nÞ=C20: ð4Þ
Thus, the percentiles of the sampling distribution for b1 in this
special case are exactly complementary to those of the sampling
distribution of the mean background DNA adduct concentrationC0, i.e., an upper 95% conﬁdence bound on the regression slope esti-
mate b1 corresponds exactly to a lower 95% conﬁdence bound on
the mean background DNA adduct concentration.
When the additional uncertainty associated with individual
background risk estimates P0i is considered, so long as there is no
covariance between the P0i and C0i, as is the case here, the regres-
sion estimate of b1 remains the same as that given by equation A1.
However, the estimated variance of b1 changes to:
Varðb1Þ=b21 ¼ðVarðC0Þ=nÞ=C20 þ ðVarðP0Þ=nÞ=P20Þ
 ½1þ ððn 1Þ=nÞ  VarðC0Þ=C20; ð5Þ
where Var(P0) represents the variance of the individual background
risk measurements P0i. Thus, the upper 95% conﬁdence bound esti-
mate for the regression slope estimate b1 is increased as a result of
incorporating the additional uncertainty associated with the indi-
vidual background risk estimates P0i.
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